Nanosonics Limited (NAN) Earnings Call Transcript
August 25, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Nanosonics FY '26 Full Year Results Investor Briefing. I'm Catherine Strong, Head of Investor Relations at Nanosonics. Michael Kavanagh, our Chief Executive Officer and President, will lead today's presentation, along with Jason Burriss, Chief Financial Officer. Management is going to walk through a number of slides that were filed with the ASX earlier this morning. After the briefing, there will be a question-and-answer session. <<operator_script>> At this point, I'd like to turn the call over to Michael Kavanagh. Please go ahead, Mike.
Thanks a lot, Catherine, and good morning, everyone, and thanks to all of you for being with us today. By this point, many of you will already have reviewed the FY '26 results. There is plenty of information in the materials that were lodged this morning; but before we dig into some of those details, I want to highlight a number of key takeaway messages. Starting with constant currency, which obviously provides a better view of underlying performance: FY '26 came in strong, with revenue on that basis rising 6% over the year and EBIT climbing 21%, helped — as you'll have noticed — by tight cost discipline even as we continue putting money into future growth. Second, the trophon-only business. It turned in the best placement result we've seen in three years — more than 4,200 units were placed over the course of the year. That lifted the cumulative installed base past 39,000 devices in the field as of today, and we also posted record upgrade activity in North America. On top of that, we brought our next-generation technologies to market successfully: trophon3 and trophon2 Plus. Importantly, for the year, the trophon-only business delivered EBIT of $50.6 million on a reported basis, or $56.5 million in constant currency, which is up 16%. That continues to show the strong profitability, cash generation and operating leverage we're getting from the trophon business. Number three, and this matters a lot, is that CORIS remains on track, with the important regulatory clearances secured and controlled market release work moving forward in each of the markets where we'll launch. You'll also be glad to hear that we now expect the commercial launch to happen in the second half of FY '27. With CORIS coming to market soon, I'd say the company is clearly heading into what we see as a pivotal stretch of fresh growth, since we're shifting from one platform to being a multi-platform infection prevention business. And we're certainly going into FY '27 from a strong position, with trophon still delivering solid profit and cash. Our balance sheet carries no debt, which gives us room to put money into CORIS—and you'll have seen this morning's news that we're handing more capital back to shareholders through a $40 million buyback. Now for a few specifics. Revenue as reported came in at $203.9 million, a touch below $204 million, marking a 3% rise over PCP. On a constant currency basis, though, it was $211.5 million, which works out to 6% growth. One thing worth highlighting is that during Q3 of this year, we saw some softness in consumables, which lined up with the severe weather events that hit the Northeast of the United States—many of you likely saw coverage of those. It was covered extensively in news outlets worldwide at the time. We observed that this led to reduced traffic at hospitals. And we did see, when it came to shipments into that whole region, a decline in our consumables shipments; however, the important takeaway is that this is not structural, because consumable volumes did bounce back in Q4. Also during Q3, we had been anticipating a bit more trophon3 versus trophon2. As you may remember, during the first half the mix was weighted toward trophon2, whose price is below that of trophon3. And although trophon3 grew in the third quarter, trophon2 still accounted for a meaningful percentage, which put some pressure on ASP. But once more, what matters is that Trophon3 became the leading device in Q4, and we see that carrying on into this year as well. So ASP did go up. So the effect was modest. So what we saw in Q3 was largely some transitional effects rather than anything structural. For the full year, gross profit margin was 76.9%, and the 1.3-point decline versus FY '25 was due to product mix, given those record capital unit placements, since capital unit gross margin sits below that of consumables. Currency movements also played a part. Even so, in constant currency terms, gross margin is still a very healthy 77.6%. Operating expenses were tightly managed throughout the year without cutting back on growth investments, rising just 2% as reported and 4% at constant currency. Putting all of that together, we delivered reported EBIT of $16 million for the year, or $21.6 million on a constant currency basis, which represented a 21% increase over the prior year. From an operations standpoint, we delivered a solid result. The strength of the trophon-only business deserves mention, and it continues to be a consistent element of Nanosonics' performance. As Jason will discuss shortly, the trophon franchise keeps producing robust profitability and cash flow. For the year, the trophon-only business reported EBIT of just under $51 million, or just under $57 million in constant currency, representing a 16% increase over the prior corresponding period. Put simply, trophon remains a highly profitable engine that gives us the flexibility to fund CORIS, keep our balance sheet debt-free and continue investing for the long term. Fiscal '26 also brought significant operational achievements throughout the entire company. Some highlights I've already covered, but a few deserve a closer look when it comes to overall progress. Within the trophon franchise, we introduced trophon3 along with trophon2 Plus, the latter arriving midway through the first half, and adoption of these new products picked up during the second half, especially in Q4. Globally, our cumulative installed base rose 6%, reaching 39,230 units. Importantly, that translates into roughly 31 million patients shielded each year from cross-contamination risk. Upgrades remained strong, climbing 20% over the year. Also significant: North America saw a 32% rise in upgrades. More than 8,000 of the older first-generation trophon EPR units across North America are still awaiting upgrade, so a substantial opportunity lies ahead. Turning to CORIS, we hit key regulatory and commercial milestones this year — clearances in the U.K., Europe and Australia, along with our first FDA 510(k) clearance, which covers the initial round of expanded scope indications. That second 510(k) has been submitted to the FDA and is under review. As I mentioned before, we begin commercial launch during this first half. To help make all this possible, we continued bolstering operations over the course of the year. In addition to establishing a specialized production line in Australia for CORIS devices, we enlarged our Indianapolis site in the U.S., and manufacturing plus distribution of trophon's main consumables has now started from that local Indianapolis facility. The CORIS QUANTUM consumable line has likewise been installed in Indianapolis and is fully prepared. I'd add that during Q3 of this year, our corporate headquarters, manufacturing operations and laboratories will relocate to a new site very near where we are now in Macquarie Park — all to support the coming stage of our growth.
And in this fiscal '26 year, that site did get registered, and every regulatory approval needed for manufacturing was secured. Capital works are all in progress at the moment as we get ready for the move in Q3. So let me go back briefly to the trophon business. As I said, placements for trophon totalled 4,230 units. That's a 9% increase versus the prior year. And it does mark the strongest annual placements we've achieved in 3 years. Within that total, the cumulative installed base rose 6% to 39,230 devices, with 2,230 new installed base units added over the year. I've already mentioned the upgrade, a record year. 2,000 units, though most of those, 1,980 to be exact, were in North America, which was up 32%, and we expect continued growth there. So overall, a very strong year for total unit volumes. Before I pass to Jason, who'll go through some of the financials in more detail, I think it's worth noting that with the commercial launch of CORIS now imminent, we believe Nanosonics is entering an exciting new phase. With CORIS, we have the chance to apply the proven commercial foundations built through trophon. That covers our customer relationships, our sales and service capability, the regulatory and clinical expertise we've developed, our manufacturing capability and, of course, the proven recurring revenue model, all applied to a second highly significant infection prevention opportunity. So while CORIS is a new platform, I believe we're launching it from a position of strength, and we certainly do believe it has the potential to become our second transformational growth platform, an important driver of long-term value for Nanosonics. But more on this a little bit later. I'll now hand over to Jason to take you through the — some more of the details around the financials. Jason?
Thanks, Michael. As you mentioned, I'll walk you through the finer points of the FY '26 results. For Nanosonics, FY '26 delivered solid earnings growth on a constant currency basis along with disciplined management of operating expenses. EBIT rose 21% in constant currency terms, underpinned by revenue growth and tight control of operating expenses. We're also still seeing operational leverage within the trophon-only business. At the same time, we put investment into CORIS, which we expect to become a second growth engine for the company. In addition, we returned $20 million to shareholders via the buyback, with a further buyback of up to $40 million announced today. Now to the P&L. Revenue came in at $203.9 million, an increase of 3% on a reported basis and 6% in constant currency terms to $211.5 million. Gross profit margin was 76.9%, a moderation of 1.3 points, which reflected product mix along with the impact of a stronger Australian dollar relative to the U.S. dollar. On a constant currency basis, gross profit margin stood at 77.6%, just 0.6 points below last year; and as Michael noted earlier, this is mainly tied to higher capital unit sales, which is clearly a positive for the long-term benefit of the business; we recovered $2.5 million in U.S. tariffs that had been paid under the International Emergency Economic Powers Act through February 2026. Those are included in our FY '26 financials. Our residual FY '26 tariffs, meaning the ones that hit the P&L, came to $0.6 million, which makes them comparable with FY '25, when we paid $0.5 million. Operating expenses were $141.4 million, up 2% on a reported basis and 4% at constant currency, reflecting disciplined cost management. And of course, within OpEx, trophon costs were $106.8 million, down 1%, while the investment went into CORIS, which lifted the OpEx spend by roughly 13% to $34.6 million as we kept preparing for launch. OpEx, of course, included R&D, which continued to decline as a percentage of sales, from 17% in FY '25 to 16% in FY '26, as the new trophon technology reached the market. EBIT was $16 million on a reported basis, or $21.6 million in constant currency, which is a 21% increase in constant currency terms. Looking specifically at capital revenue, we report growth of 4% to $54.7 million, or 8% in constant currency terms. The result was mainly driven by higher volumes, with North America remaining the key growth driver and delivering record placements, including record upgrades. Pleasingly, average selling price strengthened during the second half of the year as trophon3 made up a larger proportion of sales. We also saw trophon2 Plus software upgrades contributing more strongly in Q4, and we expect that momentum to carry into FY '27. Moving to annuity revenue. On this slide, we share the growth in annuity revenue. As a refresher, annuity revenue is recurring revenue less spare parts, which has become a suitable metric for Nanosonics because it gives a clearer view of the underlying quality, resilience and growth of the recurring revenue base. Annuity revenue increased 4% as reported, reaching $141.8 million, which equals 8% growth in constant currency terms. Core consumables — the trophon disinfectant plus chemical indicators that get used in each cycle — rose 4% at constant currency. Ecosystem revenue was up 6% at constant currency, and ecosystem products cover the broader lineup of trophon workflow items, such as probe covers, cleaning wipes and additional consumables. Service revenue climbed 19% at constant currency, expanding strongly as a growing number of customers take up the service offerings tied to both Trophon2 and Trophon3. Service comprises preventative maintenance and support contracts, together with our pay-as-you-go customers. Spare parts eased as anticipated while customers moved to newer trophon systems and following the record upgrade result in North America. Now to our regional performance. North America delivered record total placements and upgrades in FY '26. We placed a record 3,880 devices this year, an increase of 13%. Upgrades drove that growth, at 1,980 units, up 32% versus the prior year, while the new installed base kept expanding, adding 1,900 units. Upgrades will remain a meaningful opportunity for Nanosonics in North America. As Michael mentioned earlier, roughly 8,000 original EPR devices are still out there for potential conversion. Those new installed base additions bring our cumulative installed base in North America to 34,210 devices, up 6%. And naturally, each device represents a multiyear stream of consumables, ecosystem and service revenue. A bigger base therefore directly widens the annuity foundation. North America reported revenue was $186.4 million, up 3%, or 8% at constant currency, which shows underlying demand stays strong in that region. Reported annuity revenue came to $126.8 million, up 4%, or 9% at constant currency; annuity revenue within core consumables rose 5%, and the service business grew 19%. Both of those figures are constant currency. Reported capital revenue was $52.3 million, up 6%, or 10% at constant currency, driven by the record placement activity just discussed and, as noted already, by improved capital pricing in the second half as trophon3 made up a larger share of sales and uptake of trophon2 Plus upgrades increased in the fourth quarter. Spare parts, which sit outside annuity revenue, were $7.3 million, down 21%, or 19% at constant currency, and we expect further moderation as customers upgrade to newer trophon systems. On the whole, North America remained a strong performing region for us. In EMEA and APAC, we keep growing the cumulative installed base. Turning to EMEA. Our cumulative installed base rose 8% versus the prior year to 2,630 units, with 200 new units added, consistent with last year. In this region, most of the original trophon EPR fleet has already been upgraded. Reported annuity revenue increased 7%, while total revenue grew 1% to $12.3 million, driven by a moderation in capital revenue. Capital revenue was softer because we saw a larger proportion of the managed equipment service model rather than the capital purchase model in the U.K. compared with last year. Just to remind everyone, units bought through the MES model carry no upfront capital revenue, which means the capital value gets folded into a higher consumables price. Moving on to APAC. New installed base devices rose by 130 units, a 44% increase versus the prior year, with a solid contribution from Japan. That lifted the cumulative installed base to 2,390 units, which reflects 6% growth. Total units placed came to 150, including 20 upgrade devices, in a region where most EPR units have already been upgraded. APAC reported revenue was $5.1 million, 14% lower than the prior year. Annuity revenue came in at $4.2 million, also down 14%, and capital revenue was $0.9 million, a decline of 18%. The capital weakness came from placement mix, especially in Japan, where most units went out under a rental model. Annuity revenue also came under pressure; even so, we think our next-generation trophon offering is compelling, and continued strong momentum in device sales should help support annuity revenue going forward. Nanosonics continues to be in a strong financial position. We closed FY '26 with $155.2 million in cash and cash equivalents. Business cash flow, which leaves out the funds used for the share buyback, was $13.6 million, reflecting robust cash generation from trophon while also funding CORIS commercialization and an inventory increase to support trophon growth and the CORIS launch. We also finished a $20 million share buyback in FY '26, returning capital to our shareholders. And as Michael noted, we announced another buyback of up to $40 million for fiscal year '27. In our view, this is an attractive and efficient way to return capital to shareholders while keeping the capacity to invest for long-term growth. Before I hand back to Michael, I think it's worth highlighting how strong the trophon-only business is. It sits at the center of our growth strategy thanks to its earnings power and strong cash generation. EBIT for the trophon-only business was $50.6 million, up 5%, or $56.5 million in constant currency terms, up 16%. The strong financial profile of the trophon business is what lets us invest in CORIS, keep innovating and maintain the balance sheet flexibility we have; that covers the financials. Michael, I'll hand back to you to talk more about trophon and CORIS and our guidance for fiscal year '27.
Thanks so much, Jason. First off, a few remarks about what we anticipate for the trophon business in FY '27. We do anticipate continued robust expansion in the trophon franchise. Trophon continues to be a market-leading growth platform, with several capital and recurring revenue levers—as shown on this slide—that we believe can keep expanding revenue, earnings and, naturally, customer value. On the capital side, we do expect the installed base to keep growing across every region. We continue to grow the new installed base in North America, and we expect trophon3 to keep doing that. In EMEA, trophon3 does reinforce our customer proposition and potentially underpins even more country-level opportunities as adoption fundamentals get better. Over in Japan, we're definitely gaining ground on the foundational pieces needed for broader uptake, such as creating local guidelines, and we anticipate regulatory approval for trophon3 within this half as well. And, as Jason mentioned, Japan added solidly to APAC's unit numbers in FY '26. Staying with capital for a moment, upgrades continue to represent a meaningful opportunity. FY '26 showed us terrific growth in that area. Beyond simply refreshing the installed base, these upgrades frequently open up additional service possibilities and workflow benefits, since—worth remembering—a lot of those legacy EPR units had traditionally been covered by service agreements with GE Healthcare. So when we sell an upgrade, Nanosonics picks up the new service contract. Beyond that, the trophon2 Plus software upgrades give us a means of adding value throughout the installed base of trophon2 units, which numbers well over 25,000. And in Q4 we began to see those trophon2 Plus software upgrades pick up speed. As a result, we do expect a meaningful contribution from them in FY '27. So on the whole, we expect upgrades to remain a continuing growth driver as we move forward. Turning to annuity revenue, I think the core consumables grow alongside procedure utilization; and as I mentioned earlier, although we saw some softness in Q3, that reversed as we went into Q4 and in these early stages of FY '27. Consumables therefore scale alongside procedure utilization, and the consumables in our ecosystem give us a chance to expand our portion of the complete workflow. As I noted, service likewise remains a significant and substantial growth avenue and performed very well in FY '26. And having those service contracts in place certainly delivers value to customers, while also creating strong retention opportunities. Lastly, connectivity: in time, we believe connectivity subscriptions — particularly now with our new DICOM and the capabilities within trophon3 — will grow more significant going forward. All told, trophon continues to be a premium, high-growth platform offering several avenues for sustained revenue expansion, profitability and cash flow, and our guidance captures all of that. Since trophon is still producing solid earnings growth, I want to turn briefly to CORIS, which we view as the next major leap in moving Nanosonics past ultrasound reprocessing by itself. CORIS is approaching commercial launch in the first half. Without question, this represents a significant milestone for Nanosonics and its shareholders, and it signals a transition away from many years of technology development, regulatory effort and controlled market release work toward the beginning of commercial uptake. The chance for CORIS is a big one — about 60 million endoscope procedures happen each year in the markets we're going after. And importantly, CORIS tackles a genuine, serious issue in endoscope reprocessing. Right now, cleaning the channels of flexible endoscopes is one of the toughest jobs out there. It's done by hand, it involves lots of steps that vary across the whole reprocessing workflow, and it's difficult to standardize, difficult to verify, and difficult to do the same way every time when channels are complex, narrow, and often branching. That's precisely what we observed in our controlled market release, and it's the problem CORIS was designed to fix. For customers, CORIS delivers what I see as a clear value proposition: automation, better efficacy, and consistent outcomes. The system checks all the important cycle parameters, and that makes tracing easier. It offers workflow assistance to the staff who have to carry out this task and, in the end, assurance that this essential step was performed well. Each of these benefits is a practical, believable reason for hospitals to take it on, since they relate directly to patient safety, quality assurance, compliance, and operational efficiency. All of those areas matter greatly when a new technology is being brought in. The slide you see before you—and which is also in the investor deck—explains our confidence that CORIS can develop into an extremely appealing business down the road. At present, I think trophon is the most useful benchmark available to investors. With trophon, every installed unit creates recurring revenue over the long term via consumables, service, and the wider workflow products. As we described today, that installed-base approach has yielded high-quality annuity income, robust gross margins, operating leverage, and considerable cash generation. CORIS rests on the very same foundational principles. Its capital equipment, though, is projected to cost three to five times what trophon currently does. Each unit is anticipated to average roughly 10 cycles daily, which once more is 3 to 4x trophon's figure. The price for each cycle should run about four to six times what trophon costs. For equipment in this category, service uptake ought to be stronger than trophon's as well — that sits around 55% to 60% today, while technologies such as these can reach 80% to 100%. So the investment case is clear. Without question, CORIS provides Nanosonics with a second platform carrying annuity characteristics similar to trophon's. It addresses a substantial unmet need and rests on commercial capabilities we have already demonstrated. That is why we are confident CORIS unquestionably can become a significant long-term value driver for Nanosonics. On the launch, we will start this half in the U.K., Ireland and Australia, along with the U.S. That will also arrive at a later point in the year. Across that initial launch period, our emphasis is going to be on generating widespread market awareness, developing pipeline as we head into customer budget cycles, and naturally on landing our first customers and reference site adoptions by way of preparation — all of which gets us ready for acceleration in FY '28. Within this year, we do anticipate revenue from CORIS to materialize, though, as numerous analysts have projected, we expect it to land in the low single-digit millions, which, as I mentioned, is what many analysts have forecasted for a launch year. As one would expect with a launch, we are purposefully stepping up our investment in CORIS during FY '27. The money is going toward growing our dedicated CORIS launch capability, and part of it will fund additional endoscope reprocessing sales specialists. Those specialists will back up our current sales team, along with clinical and application support, field service, and installation support. Given how large the opportunity tied to CORIS is, we think this is the best use of our capital at present. One thing I should mention: we still expect the trophon business to continue producing operating leverage and cash generation—robust cash generation in FY '27—which leaves us room to invest behind CORIS.
Therefore, most of the OpEx rise you are observing in FY '27 comes directly from the CORIS commercial launch. For Trophon, we anticipate that we will keep delivering operating leverage as well as cash generation. So, with that said, let me turn to our outlook and guidance for FY '27. As I noted, we came into this year with momentum in trophon, a strong balance sheet, and now a clear path for investing in the CORIS launch while keeping capital allocation disciplined. On a constant currency basis, our expectation for FY '27 revenue is $220 million to $228 million for the year, representing growth of 8% to 12% over FY '26, and as already noted, CORIS should deliver initial revenues in the low single-digit million. So most of that is tied to continued trophon growth. We expect our gross profit margin to land between 74%, 76%, and that mirrors the higher tariffs Jason already referenced, which stand at 12.5%, plus freight effects from the higher volumes we are shipping and increased freight pricing caused by geopolitical situations. Operating expenses are expected to come in between $156 million and $163 million. And as noted, the absolute majority of that OpEx growth is tied to CORIS, including the step-up in investments for the CORIS launch that I mentioned. So for trophon, once again, we are aiming for further operating leverage improvements as that business keeps performing; and finally, you will have seen this morning as well, and we have already noted, we are launching a share buyback of up to $40 million, which follows the $20 million we completed in FY '26. And the decision to initiate another on-market buyback, I think, mirrors the strength of our balance sheet, the cash generation of the business, and also the confidence we hold in the outlook ahead while continuing to invest in our long-term growth strategies. So with that, I will now hand back to the operator and open the call for questions.
Michael, maybe I could pick up right where we left off concerning the additional OpEx within CORIS. Could you spell out more precisely what that extra investment will be paying for during this year? And would it be fair of me to assume that CORIS's new OpEx baseline would hopefully become more or less steady, say, by the time we get to '28 and '29? As things stand, you can understand it's pretty difficult to predict exactly when that part of the business will reach break even.
Yes. That's a great question. Appreciate that, Shane. We're moving toward launch at this point, and most of that added operating expense is being deployed into the regions—not really here at headquarters, but out in the regions, where we're going to bring on additional headcount to back the CORIS franchise. Naturally, we'll be drawing on the infrastructure already in place. Still, as we've consistently said, upon launch we'll bring in extra specialist support for the CORIS franchise—so specialist salespeople will be joining, though not at the scale of the trophon sales team; rather, a specialized sales group will be added. What we'll need going forward is personnel to handle the project management and installation expenses—this differs from trophon, which can be shipped and basically plugged in alongside CORIS, with you working through the hospital facilities department and handling project management to confirm that all required infrastructure, the water lines and so on, is in place ahead of installation. So conventionally, for equipment of this kind, you have staff on site who project manage that together with the hospitals. That means more resources there, plus certain specialist resources for our clinical applications and education. Beyond that, naturally, we have launches underway, which means marketing expenditure will rise. That said, my view is that as we move into FY '28, FY '27 becomes the reference point, and you ought not to expect step-up shifts — including in CORIS at that point. The bulk of the significant added investment gets made in the current year.
That's great. For my second question, I really want to go back to the consumables part. I heard your comments about ultrasound procedural volumes moving around somewhat; but could you perhaps help us by giving some figures on that, maybe if we looked at the difference between the third quarter and the fourth quarter in percentage terms, what would it be? And maybe how did the fourth quarter compare with what you saw in the first half?
Yes. I think if we see that softness in Q3, and I do want to repeat, we didn't see that softness carry on into Q4. It turned around; and when we went back and examined it, we could actually see shifts in our shipments, particularly to that entire customer base across the whole Northeast of the U.S. You probably would have added another $2 million in consumables to the business in Q3. So it did have an impact, but that's why we feel confident as we head into FY '27 on the consumables front.
One final question from me. Did you notice — I mean, when I line up my EMEA model, I kind of picked up on somewhat softer utilization. Is there anything worth flagging regarding the utilization trends you're observing in that region, just aware that some different kinds of effects are at play there and could be <<inaudible>>.
Within the NHS — and this has been publicized — there's severe pressure in sonography. Relative to demand, the count of sonographers available is far smaller; they genuinely regard this as a major problem over there. So you're likely correct. Although we did see some growth, you're likely correct that procedural volume took a hit. We believe it would have been affected considerably by what was going on in the NHS. We certainly would have wanted more to come out of Europe during the year, no question. We believe that now, following the trophon3 launch and as we head into this year, our forecasts for this year are definitely higher.
I'll start with a question about CORIS and a few of the economics you laid out there, which is useful. On the consumables side, could you remind us — as we try to establish a base for price per cycle in the current environment, perhaps in U.S. dollar terms — where you believe that sits right now for the trophon business, even if only in broad terms?
As we've consistently stated, cleaning a device today costs somewhere between — anywhere from USD 10 up to USD 30, depending on the level of detail. So if you consider the trophon price, the anticipated price of the core consumable comes in toward the lower end, not the very lowest end of that range, but toward the lower end of it.
Sorry, CORIS price, you mean?
CORIS.
CORIS. Yeah. All right, so we're going toward the bottom of that range. Okay. Understood. And after that...
<<inaudible>> and that's still a sizable jump.
Right, just to clarify, the range is USD 10 to USD 37, which we discussed earlier, so we're leaning toward the lower end of it.
Yes. Understood. All right, so 4 to 6x regarding price per cycle; and I believe you mentioned on utilization, 10 cycles per device per day. Yes. Okay. That is genuinely useful. And just to clarify what Shane asked earlier about the OpEx step-up from CORIS. So as you put it, you have a fair amount when it comes to installation-related teams, like as you ramp up and how we should — obviously, into the U.S., the bigger market. So you are saying only into '28 and other years, we should only see more incremental cost growth coming through in terms of — from there on out. There is no sort of major step-up, just confirming that.
Yes, beyond this year we are not expecting double-digit step-up increases in OpEx and CORIS; this year is the big — the launch year is, as you would expect, the big investment year from a commercialization perspective.
Understood. That is genuinely useful. And then, too, just regarding the trophon, you brought this up on the call, and I apologize if you already clarified it, but the ASP pricing and a few of those matters you also saw, it sounds like they got better toward the end of the year. Could you give us a sense of whether that's roughly back to the levels we ought to be expecting? And going forward, is it mainly T3s that should account for the incremental new installed base sales?
Yes. Michael, I can take that question. Yes, pricing in the second half was encouraging; it came back toward the levels of the previous year; and that really happened because of the shift toward T3; and as Michael said, given the long pipeline, or the long sales cycle on some of the bigger deals, we still sold more T2 in the second half than we expected, certainly at the time we released the first half results; so as that mix has shifted toward trophon3 and our customers recognize the added value, we have seen pricing get better. And as the mix improves in '27, I would expect us to see further improvement.
Okay. No, that's genuinely useful. And one last thing, guys, just regarding how we take CORIS to market. So clearly there are several different models you could choose for selling it, but you have a very solid balance sheet and plenty of cash. Apologies if this has come up already, but as you expand into the market across the first few years, how should we frame the funding approach — does it remain capital, could you possibly consider additional MES models, and perhaps just take us through what some trial clients have said at the outset and where you believe the market holds more strength and is more apt to drive growth?
Yeah, Josh, what you'll end up seeing is genuinely going to be a combination of things. The nice part is that having the balance sheet as strong as ours is right now gives us that kind of flexibility. The key priority is driving unit placements. Consumables are central to this, since the gross margin levels you're describing for CORIS consumables will be comparable to those you've seen with trophon. So the mix will include some capital sales—that's simply what the market demands and what customers want to do. Rentals will also be part of the mix; we have the option to lease, to place units, and to do MES-style arrangements that sit on our balance sheet. We may end up seeing more MES-type deals in the U.K. and more capital sales in the U.S.
I'd like to spend a moment on consumables for FY '26. Looking at how the first half and second half might play out, and I know you've flagged some utilization headwinds in the U.S. market. That said, was there any kind of stocking up activity during the first half that maybe diluted growth in the second half, given that you did raise prices in connection with U.S. tariffs, would you say?
Yes. Thanks for the question, Davin. From my perspective, nothing stood out as unusual restocking or anything driven by pricing. What gave us confidence going into FY '27 regarding the growth figures and guidance we've provided was the rebound in Q4 along with better volumes. The information available to us, including results from several big U.S. hospitals, shows patient visits decelerated during the third quarter, and that's what we connect it to.
Yes. That's completely fine. And sorry for cutting in on this — I figure it's a big thing the market is watching, especially with some of the questions about how competition has shifted here. So I also wanted to get clarity: do you believe the trophon EPR discontinuation might have impacted your consumables business? Or does the Q4 and year-to-date trading in '27 show that the majority of those units are getting upgraded and essentially no one is delaying and continuing to use your consumables?
Yes. Well, that's a fair question. In the U.S., the market is definitely more competitive, yet we've set placement records there over the past three years. So we aren't really seeing signs of meaningful customer loss to rivals stateside. There have been cases, particularly among the bigger deals we've closed, where competitors were part of the evaluation. And among those large deals where we faced competitive evaluation, we didn't lose a single one. I believe there are a lot of reasons for that, given the value propositions and the data we hold on trophon; so most of the consumables we're seeing were really on the traffic side. It would be naive of me to think we'll keep 100% market share, and some units may be affected, because we do see it publicly — you've got Tristel growing in the United States. But for the trophon customers there, if they're low-volume users, a few like that may have used Tristel. We've also seen some Tristel customers come back to trophon. Broadly speaking, the main issue is really the traffic situation Jason brought up. Still, that's a matter we need to stay actively watchful about.
Yes. And this is my last question. Regarding the CORIS pricing strategy and that 3 to 5x on the capital side — I get that you plan to use different sales models. But what gives you the conviction behind an increase of that magnitude? And tied to that, on the initial contribution you expect in FY '27, could you tell us roughly how the weighting would break down? Is it mostly upfront capital sales, or do you think the consumable side carries more weight?
On the capital price, our conviction there rests on pricing research we've carried out. Once customers see the value proposition and how sophisticated the technology is, and you compare it against a comparable type — against what they pay for AERs — it remains far below that, and yet it performs a job that's just as important, and in certain cases is more advanced technologically; so we feel fine about the capital pricing. As for the mix of consumable versus capital in the — for this year, it's a bit early to tell; but on the capital side, as I said, we'll see a range of models. It could — it may turn out to be 50 to 50 between capital placement and capital rental, but we'll see how that develops.
Thanks so much. Well, once more, I appreciate everyone being here. I realize it's an extremely busy day and an extremely, extremely busy season; however, let me repeat what I noted at the beginning, we think that on a constant currency basis, this is a solid result for the business financially, operationally, and many key things have been accomplished over the last 12 months. What's exciting is that we're now moving into the CORIS launch phase, which we're all very excited about. And we definitely head into this new year with strong momentum. So once more, thanks for everyone attending, and I look forward to catching up with many of you over the coming days.
Thanks; that brings today's conference to a close. We appreciate your participation. You can disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nanosonics Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.